Advanced search
Publication Cover
OncoImmunology Volume 8, 2019 - Issue 11
Submit an article Journal homepage
4,838
Views
19
CrossRef citations to date
0
Altmetric
Original Research

Dexamethasone differentially depletes tumour and peripheral blood lymphocytes and can impact the efficacy of chemotherapy/checkpoint blockade combination treatment

Wayne J. AstonNational Centre for Asbestos Related Diseases, The University of Western Australia, Nedlands, WA, Australia;Medical School, The University of Western Australia, Nedlands, WA, AustraliaORCID Iconhttps://orcid.org/0000-0003-2736-419XView further author information
ORCID Icon,
Danika E. HopeNational Centre for Asbestos Related Diseases, The University of Western Australia, Nedlands, WA, Australia;School of Biomedical Sciences, The University of Western Australia, Nedlands, WA, AustraliaORCID Iconhttps://orcid.org/0000-0001-5312-4355View further author information
ORCID Icon,
Alistair M. CookNational Centre for Asbestos Related Diseases, The University of Western Australia, Nedlands, WA, Australia;Medical School, The University of Western Australia, Nedlands, WA, AustraliaORCID Iconhttps://orcid.org/0000-0001-5339-5374View further author information
ORCID Icon,
Louis BoonBioceros, Utrecht, The NetherlandsORCID Iconhttps://orcid.org/0000-0002-0937-9171View further author information
ORCID Icon,
Ian DickNational Centre for Asbestos Related Diseases, The University of Western Australia, Nedlands, WA, Australia;School of Biomedical Sciences, The University of Western Australia, Nedlands, WA, AustraliaORCID Iconhttps://orcid.org/0000-0003-1902-9033View further author information
ORCID Icon,
Anna K. NowakNational Centre for Asbestos Related Diseases, The University of Western Australia, Nedlands, WA, Australia;Medical School, The University of Western Australia, Nedlands, WA, Australia;Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, WA, AustraliaORCID Iconhttps://orcid.org/0000-0002-9317-9526View further author information
ORCID Icon,
Richard A. LakeNational Centre for Asbestos Related Diseases, The University of Western Australia, Nedlands, WA, Australia;School of Biomedical Sciences, The University of Western Australia, Nedlands, WA, AustraliaORCID Iconhttps://orcid.org/0000-0002-7765-602XView further author information
ORCID Icon &
W. Joost LesterhuisNational Centre for Asbestos Related Diseases, The University of Western Australia, Nedlands, WA, Australia;School of Biomedical Sciences, The University of Western Australia, Nedlands, WA, AustraliaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2718-276XView further author information
ORCID Icon show all
Article: e1641390 | Received 21 Nov 2018, Accepted 04 Jul 2019, Published online: 13 Jul 2019

References

  • Grunberg SM. Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. Ann Oncol. 2007 Feb;18(2):1–8. PubMed PMID: 17108149. Epub 2006/ 11/17.eng. doi:10.1093/annonc/mdl347.
  • Szatmari I, Nagy L. Nuclear receptor signalling in dendritic cells connects lipids, the genome and immune function. Embo J. 2008;27(18):2353–2362. PubMed PMID: 18716631. Pubmed Central PMCID: PMC2525841. Epub 2008/08/22.eng. doi:10.1038/emboj.2008.160.
  • Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat Rev Immunol. 2017 Apr;17(4):233–247. PubMed PMID: 28192415. Epub 2017/02/14.eng. doi:10.1038/nri.2017.1.
  • Cook AM, McDonnell AM, Lake RA, Nowak AK. Dexamethasone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo-immunotherapy strategies. OncoImmunology. 2015;5(3):16.
  • Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018 Sep 25. PubMed PMID: 30280635. Epub 2018/10/04.eng. doi:10.1056/NEJMoa1810865.
  • Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018 Apr 16. PubMed PMID: 29658856. Epub 2018/04/17.eng. doi:10.1056/NEJMoa1801005.
  • Reck M, Luft A, Szczesna A, Havel L, Kim SW, Akerley W, Pietanza MC, Wu Y-L, Zielinski C, Thomas M, et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol. 2016;34(31):3740–3748. PubMed PMID: 27458307. Epub 2016/07/28.eng. doi:10.1200/JCO.2016.67.6601.
  • Aston WJ, Fisher SA, Khong A, Mok C, Nowak AK, Lake RA, Lesterhuis WJ. Combining chemotherapy and checkpoint blockade in thoracic cancer: how to proceed? Lung Cancer Manag. 2014;3(6):443–457. doi:10.2217/lmt.14.37.
  • McDonnell AM, Lesterhuis WJ, Khong A, Nowak AK, Lake RA, Currie AJ, Robinson BWS. Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy. Eur J Immunol. 2015 Jan;45(1):49–59. PubMed PMID: 25316312. Epub 2014/ 10/16.eng. doi:10.1002/eji.201444722.
  • Lesterhuis WJ, Salmons J, Nowak AK, Rozali EN, Khong A, Dick IM, Harken JA, Robinson BW, Lake RA, de Mello RA. Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. PLoS One. 2013;8(4):e61895. PubMed PMID: 23626745. Pubmed Central PMCID: PMC3633941. Epub 2013/04/30.eng. doi:10.1371/journal.pone.0061895.
  • Cook AM, Lesterhuis WJ, Nowak AK, Lake RA. Chemotherapy and immunotherapy: mapping the road ahead. Curr Opin Immunol. 2016 4;39:23–29. doi:10.1016/j.coi.2015.12.003.
  • Garant A, Guilbault C, Ekmekjian T, Greenwald Z, Murgoi P, Vuong T. Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with hematologic or solid neoplasms: A systematic review. Crit Rev Oncol Hematol. 2017 Dec;120:86–92. PubMed PMID: 29198341. Epub 2017/ 12/05.eng. doi:10.1016/j.critrevonc.2017.10.009.
  • Bruggner RV, Bodenmiller B, Dill DL, Tibshirani RJ, Nolan GP. Automated identification of stratifying signatures in cellular subpopulations. Proc Natl Acad Sci U S A. 2014;111(26):E2770–7. PubMed PMID: 24979804. Pubmed Central PMCID: PMC4084463. Epub 2014/07/01. eng. doi:10.1073/pnas.1408792111.
  • Mishler JM, Emerson PM. Development of neutrophilia by serially increasing doses of dexamethasone. Br J Haematol. 1977 Jun;36(2):249–257. PubMed PMID: 871436. Epub 1977/06/01.eng. doi:10.1111/j.1365-2141.1977.tb00646.x.
  • Lesterhuis WJ, Rinaldi C, Jones A, Rozali EN, Dick IM, Khong A, Boon L, Robinson BW, Nowak AK, Bosco A, et al. Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations. Sci Rep. 2015;5:12298. PubMed PMID: 26193793. eng. doi:10.1038/srep12298.
  • Elsoueidi R, Lander MJ, Richa EM, Adane ED. Single-dose dexamethasone for the prevention of pemetrexed associated cutaneous adverse reactions. J Oncol Pharm Pract. 2016 Apr;22(2):271–274. PubMed PMID: 25908647. Epub 2015/ 04/25.eng. doi:10.1177/1078155215583523.
  • Maurice-Dror C, Perets R, Bar-Sela G. Glucocorticoids as an adjunct to oncologic treatment in solid malignancies - not an innocent bystander. Crit Rev Oncol Hematol. 2018 Jun;126:37–44. PubMed PMID: 29759565. Epub 2018/05/16.eng. doi:10.1016/j.critrevonc.2018.03.015.
  • Amin A, DePril V, Hamid O, Wolchock J, Maio M, Neyns B, Ibrahim R, Hoos A, O'Day S.Evaluation of the effect of systemic corticosteroids for the treatment of immune-related adverse events (irAEs) on the development or maintenance of ipilimumab clinical activity. J Clin Oncol. 2009;27(15S):9037.
  • Harmankaya K, Erasim C, Koelblinger C, Ibrahim R, Hoos A, Pehamberger H, Binder M. Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy. Med Oncol. 2011 Dec;28(4):1140–1144. PubMed PMID: 20593249. Epub 2010/ 07/02.eng. doi:10.1007/s12032-010-9606-0.
  • Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007;13(22 Pt 1):6681–6688. PubMed PMID: 17982122. Pubmed Central PMCID: PMC2147083. Epub 2007/11/06.eng. doi:10.1158/1078-0432.CCR-07-0187.
  • Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, Carvajal RD, Dickson MA, D’Angelo SP, Woo KM, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center. J Clin Oncol. 2015;33(28):3193–3198. PubMed PMID: 26282644. Pubmed Central PMCID: PMC5087335 online at www.jco.org. Author contributions are found at the end of this article. Epub 2015/08/19.eng. doi:10.1200/JCO.2015.60.8448.
  • Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, Sznol M, Long GV, Li H, Waxman IM, et al. Safety profile of nivolumab monotherapy: A pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017 Mar;35(7):785–792. PubMed PMID: 28068177. Epub 2017/ 01/10.eng. doi:10.1200/JCO.2015.66.1389.
  • Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, Martinez Bernal G, Chaft JE, Ferrara R, Lai W-CV, et al. Deleterious effect of baseline steroids on efficacy of PD-(L)1 blockade in patients with NSCLC. J Clin Oncol. 2018;36(15_suppl):9003. doi:10.1200/JCO.2018.36.15_suppl.9003.
  • Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016 Mar;7(2):27–31. PubMed PMID: 27057123. eng. doi:10.4103/0976-0105.177703.
  • Saffar AS, Ashdown H, Gounni AS. The molecular mechanisms of glucocorticoids-mediated neutrophil survival. Curr Drug Targets. 2011 Apr;12(4):556–562. PubMed PMID: 21504070. Pubmed Central PMCID: PMC3267167. Epub 2011/04/20.eng.
  • Xing K, Gu B, Zhang P, Wu X. Dexamethasone enhances programmed cell death 1 (PD-1) expression during T cell activation: an insight into the optimum application of glucocorticoids in anti-cancer therapy. BMC Immunol. 2015;16:39. PubMed PMID: 26112261. Pubmed Central PMCID: PMC4480888. Epub 2015/ 06/27.eng. doi:10.1186/s12865-015-0103-2.
  • Herr I, Ucur E, Herzer K, Okouoyo S, Ridder R, Krammer PH, von Knebel Doeberitz M, Debatin K-M. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas. Cancer Res. 2003 Jun 15;63(12):3112–3120. PubMed PMID: 12810637. Epub 2003/06/18.eng.
  • Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, Martin F, Apetoh L, Rébé C, Ghiringhelli F. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010;70(8):3052–3061. PubMed PMID: 20388795. Epub 2010/04/15.eng. doi:10.1158/0008-5472.CAN-09-3690.
  • Wang Z, Till B, Gao Q. Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells. Oncoimmunology. 2017;6(7):e1331807. PubMed PMID: 28811975. Pubmed Central PMCID: PMC5543863. Epub 2017/08/16.eng. doi:10.1080/2162402X.2017.1331807.
  • Klement JD, Paschall AV, Savage NM, Nayak-Kapoor A, Liu K. 5- Fluorouracil regulation of myeloid-derived suppressor cell differentiation in vitro and in vivo. J Immunol. 2017;198:205.5.
  • Hato SV, Khong A, de Vries IJ, Lesterhuis WJ. Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics. Clin Cancer Res. 2014;20(11):2831–2837. PubMed PMID: 24879823. Epub 2014/ 06/01. eng. doi:10.1158/1078-0432.CCR-13-3141.
  • Ramakrishnan R, Assudani D, Nagaraj S, Hunter T, Cho HI, Antonia S, Altiok S, Celis E, Gabrilovich DI. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest. 2010 Apr;120(4):1111–1124. PubMed PMID: 20234093. Pubmed Central PMCID: PMC2846048. Epub 2010/03/18.eng. doi:10.1172/JCI40269.
  • Lesterhuis WJ, Punt CJ, Hato SV, Eleveld-Trancikova D, Jansen BJ, Nierkens S, Schreibelt G, de Boer A, Van Herpen CML, Kaanders JH, et al. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest. 2011 Aug;121(8):3100–3108. PubMed PMID: 21765211. Pubmed Central PMCID: PMC3148725. Epub 2011/07/19.eng. doi:10.1172/JCI43656.
  • Hato SV, Figdor CG, Takahashi S, Pen AE, Halilovic A, Bol KF, Vasaturo A, Inoue Y, de Haas N, Verweij D, et al. Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity. Oncotarget. 2017;8(33):54434–54443. PubMed PMID: 28903353. Pubmed Central PMCID: PMC5589592. Epub 2017/09/15.eng. doi:10.18632/oncotarget.17661.
  • Nowak A, Kok P, Lesterhuis W, Hughes B, Brown C, Kao S, Karikios D, John T, Pavlakis N, O’Byrne K, et al. OA08.02 DREAM - A phase 2 trial of durvalumab with first line chemotherapy in mesothelioma: final result. J Thoracic Oncol. 2018;13(10):S338–S9. doi:10.1016/j.jtho.2018.08.276.
  • Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun. 2013;13:5. PubMed PMID: 23390376. eng.
  • Mosely SI, Prime JE, Sainson RC, Koopmann JO, Wang DY, Greenawalt DM, Ahdesmaki MJ, Leyland R, Mullins S, Pacelli L, et al. Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery. Cancer Immunol Res. 2017 Jan;5(1):29–41. PubMed PMID: 27923825. Epub 2016/ 12/08.eng. doi:10.1158/2326-6066.CIR-16-0114.
  • Davies S, Dai D, Pickett G, Leslie KK. Gene regulation profiles by progesterone and dexamethasone in human endometrial cancer Ishikawa H cells. Gynecol Oncol. 2006 Apr;101(1):62–70. PubMed PMID: 16289307. Epub 2005/ 11/18.eng. doi:10.1016/j.ygyno.2005.09.054.
  • Lesterhuis WJ, Bosco A, Millward MJ, Small M, Nowak AK, Lake RA. Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity. Nat Rev Drug Discov. 2017 Apr;16(4):264–272. PubMed PMID: 28057932. Epub 2017/ 01/07.eng. doi:10.1038/nrd.2016.233.
  • Aston WJ, Hope DE, Nowak AK, Robinson BW, Lake RA, Lesterhuis WJ. A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice. BMC Cancer. 2017 October 2016. 12 Julyreceived 10 August accepted;17:684. PubMed PMID: PMC5644108. doi:10.1186/s12885-017-3677-7.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.